The U.S. Department of Veterans Affairs (VA) is at the forefront of healthcare innovation, developing cutting-edge technologies to improve the lives of veterans . Now, your business can leverage these advancements through technology transfer partnerships. Download now.

Fierce Biotech Week features insights from C-suite and executive leadership at biotech, mid-sized and large pharma companies on emerging trends and market dynamics that will help effectively prioritize R&D spend, optimize drug development and clinical operations, and navigate capital raising and partnering deals.

Fierce Pharma Week will bring together life science executives responsible for marketing and sales, medical affairs and scientific communications, new product planning and commercial development, and PR & communications to ensure pharma and biotech companies have the most integrated, agile and unified strategy needed to drive value and excel in this rapidly evolving new era.

This whitepaper outlines how life sciences companies, particularly in the pharmaceutical sector, can revolutionize their customer service operations through advanced technology and generative AI. Download now to learn more.

How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights.

The European orphan drug market presents a significant opportunity for biotech firms. Learn more about early access programs (EAPs), and how they are emerging as a critical strategy for successfully launching rare disease therapies in this complex and diverse market.

This timely whitepaper explores the capabilities life sciences companies should expect from an end-to-end automation solution to streamline compliance, increase reliability, and reduce costs. Download now.

Catalent Biologics revolutionary GPEx® Lightning system overcomes the toughest manufacturing challenges by finely tuning multi-chain gene expression resulting in optimal titer & protein quality. Experience faster development, robust processes, superior protein quality, & higher yields.

Emerging biotechnology companies must navigate complex development and approval processes for drugs, biologics, and devices – often with no previous experience. Gain the tools to move studies forward faster, by downloading WCG’s whitepaper.